Nadine Mallak

Nadine Mallak

Auto-generated profile, based on publicly available information

Nadine Mallak

Department of Diagnostic Radiology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, L340, Portland, OR 97239

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
KMKristen McClellan
Kristen McClellan
ECEmerson Y. Chen
Emerson Y. Chen
AKAdel Kardosh
Adel Kardosh
CLCharles D Lopez
Charles D Lopez
Jaydira Del RiveroJaydira Del Rivero
Jaydira Del Rivero
GPGuillaume Joe Pegna
Guillaume Joe Pegna
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogenous group of malignancies originating from neuroendocrine cells of the gastrointestinal tract, the incidence of which has been increasing for several decades. While there has been significant progress in the development of therapeutic options for patients with advanced or metastatic disease, these remain limited both in quantity and durability of benefit. This review examines the latest research elucidating the mechanisms of both up-front resistance and the eventual development of resistance to the primary systemic therapeutic options including somatostatin analogues, peptide receptor radionuclide therapy with lutetium Lu 177 dotatate, everolimus, sunitinib, and temozolomide-based chemotherapy. Further, potential strategies for overcoming these mechanisms of resistance are reviewed in addition to a comprehensive review of ongoing and planned clinical trials addressing this important challenge.

1 December 2024 in RadioGraphics
Verified
Journal Article
Closed access
LSLaszlo K. Szidonya
Laszlo K. Szidonya
TBTara Barwick
Tara Barwick
ACAmarnath Challapalli
Amarnath Challapalli
MNMitesh Naik
Mitesh Naik
AEAmy Eccles
Amy Eccles
NMNadine Mallak
Nadine Mallak
Prostate-specific membrane antigen (PSMA) radioligand therapy is an evolving treatment modality for patients with metastatic prostate cancer, offering improved survival and quality of life through a targeted and personalized theranostic approach.

27 February 2025 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
AMAnna Mench
Anna Mench
CWCeleste Winters
Celeste Winters
EMErik Mittra
Erik Mittra
LSLaszlo Szidonya
Laszlo Szidonya
CHCatherine Hess
Catherine Hess
NMNadine Mallak
Nadine Mallak
With the increasing use of radiopharmaceutical therapies, there is a critical need to appropriately inform health care professionals (HCPs) who are unfamiliar with these therapies about the radiation safety precautions required when managing recently treated patients. Clear and easily accessible instructions are essential for minimizing radiation exposure to medical staff and simultaneously reducing fear of interacting with a radioactive patient, as these factors can impact the delivery of adequate and timely medical care. In this paper, we present a workflow designed to provide clear guidelines and safety protocols for HCPs who may encounter postradiopharmaceutical therapy patients during urgent medical visits or hospital admissions. This workflow consists of 2 key strategies: an electronic medical record flag system and a physical wristband that alerts the HCP that the patient may be radioactive and includes a link to a website with detailed information. These tools ensure that HCPs who encounter these patients will have immediate access to essential radiation safety information, thereby safeguarding staff and maintaining the continuity of patient care.

1 January 2024 in RadioGraphics
Verified
Journal Article
Closed access
ASAndrew Jacob Herse Sedlack
Andrew Jacob Herse Sedlack
CMCatherine Meyer
Catherine Meyer
AMAnna Mench
Anna Mench
CWCeleste Winters
Celeste Winters
DBDennis Barbon
Dennis Barbon
NMNadine Mallak
Nadine Mallak
Radiopharmaceutical therapies (RPTs) are gaining increased interest with the recent emergence of novel safe and effective theranostic agents, improving outcomes for thousands of patients. The term theranostics refers to the use of diagnostic and therapeutic agents that share the same molecular target; a major step toward precision medicine, especially for oncologic applications. The authors dissect the fundamentals of theranostics in nuclear medicine. First, they explain the radioactive decay schemes and the characteristics of emitted electromagnetic radiation used for imaging, as well as particles used for therapeutic purposes, followed by the interaction of the different types of radiation with tissue. These concepts directly apply to clinical RPTs and play a major role in the efficacy and toxicity profile of different radiopharmaceutical agents. Personalized dosimetry is a powerful tool that can help estimate patient-specific absorbed doses, in tumors as well as normal organs. Dosimetry in RPT is an area of active investigation, as most of what we know about the relationship between delivered dose and tissue damage is extrapolated from external-beam radiation therapy; more research is needed to understand this relationship as it pertains to RPTs. Tumor heterogeneity is increasingly recognized as an important prognostic factor. Novel molecular imaging agents, often in combination with fluorine 18-fluorodeoxyglucose, are crucial for assessment of target expression in the tumor and potential hypermetabolic disease that may lack the molecular target expression. ©RSNA, 2023 Test Your Knowledge questions are available in the supplemental material.

2 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Thorvardur HalfdanarsonThorvardur Halfdanarson
Thorvardur Halfdanarson
NMNadine Mallak
Nadine Mallak
SPScott Paulson
Scott Paulson
CCChandrikha Chandrasekharan
Chandrikha Chandrasekharan
MNMona Natwa
Mona Natwa
HKHagen F. Kennecke
Hagen F. Kennecke
Radioligand therapy (RLT) with [177Lu]Lu-DOTA-TATE is a standard of care for adult patients with somatostatin-receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Taking advantage of this precision nuclear medicine approach requires diligent monitoring and surveillance, from the use of diagnostic SSTR-targeted radioligand imaging for the selection of patients through treatment and assessments of response. Published evidence-based guidelines assist the multidisciplinary healthcare team by providing acceptable approaches to care; however, the sheer heterogeneity of GEP-NETs can make these frameworks difficult to apply in individual clinical circumstances. There are also contradictions in the literature regarding the utility of novel approaches in monitoring and surveilling patients with GEP-NETs receiving RLT. This article discusses the emerging evidence on imaging, clinical biochemistry, and tumor assessment criteria in the management of patients receiving RLT for GEP-NETs; additionally, it documents our own best practices. This allows us to offer practical guidance on how to effectively implement monitoring and surveillance measures to aid patient-tailored clinical decision-making.

26 September 2022 in Surgical Oncology Clinics of North America
Verified
Journal Article
Closed access
LSLaszlo Szidonya
Laszlo Szidonya
EPEunkyung Angela Park
Eunkyung Angela Park
JKJennifer J. Kwak
Jennifer J. Kwak
NMNadine Mallak
Nadine Mallak